Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

UNIVERSITY OF NORTH CAROLINA HOSPITALS

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1989-01-01

Employees: -

Market Cap: -

Website: http://www.unc.edu/interactive-tour/unc-hospitals/

Clinical Trials

Ph II Gemcitabine, Erlotinib, and Gemcitabine With Erlotinib/Elderly Patients W/ IIIB/IV NSCLC

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: erlotinib hydrochloride
Drug: gemcitabine hydrochloride

First Posted Date: 2006-01-27

Last Posted Date: 2017-04-24

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 147

Registration Number: NCT00283244

Locations: 🇺🇸
Highlands Oncology Group - Fayetteville, Fayetteville, Arkansas, United States
🇺🇸
Summit Cancer Care, Savannah, Georgia, United States
🇺🇸
Evanston Hospital, Evanston, Illinois, United States

and more 8 locations

Biomarkers in Patients With Rectal Cancer Undergoing Chemotherapy and Radiation Therapy

Completed

Conditions: Colorectal Cancer

Interventions: Drug: capecitabine
Drug: 5-fluorouracil
Procedure: Surgical Resection
Radiation: Radiation therapy

First Posted Date: 2006-01-23

Last Posted Date: 2022-08-11

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 47

Registration Number: NCT00280761

Locations: 🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States

Whole-Brain Radiation Therapy and Pemetrexed in Treating Patients With Brain Metastases From Non-Small Cell Lung Cancer

Phase 2

Terminated

Conditions: Lung Cancer
Metastatic Cancer

Interventions: Drug: pemetrexed disodium
Radiation: radiation therapy

First Posted Date: 2006-01-23

Last Posted Date: 2017-06-23

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 10

Registration Number: NCT00280748

Locations: 🇺🇸
Alamance Oncology/Hematology Associates, LLP, Burlington, North Carolina, United States
🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States

Induction Chemotherapy Using Paclitaxel, Carboplatin, CPT-11 With Pegfilgrastim

Phase 2

Completed

Conditions: Non Small Cell Lung Cancer

First Posted Date: 2006-01-23

Last Posted Date: 2013-02-05

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 24

Registration Number: NCT00280787

Locations: 🇺🇸
University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

Ph II Adjuvant Carboplatin/Docetaxel in Curatively Resected Stage I-IIIA NSCLC

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: carboplatin
Drug: docetaxel

First Posted Date: 2006-01-23

Last Posted Date: 2017-07-11

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 75

Registration Number: NCT00280735

Locations: 🇺🇸
University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

Bortezomib, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Rectal Cancer

Phase 1

Completed

Conditions: Colorectal Cancer

First Posted Date: 2006-01-20

Last Posted Date: 2012-02-14

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 11

Registration Number: NCT00280176

Locations: 🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Lung Cancer

Interventions: Biological: bevacizumab
Drug: carboplatin
Drug: erlotinib hydrochloride
Drug: paclitaxel
Radiation: 3-dimensional conformal radiation therapy

First Posted Date: 2006-01-20

Last Posted Date: 2017-06-19

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 46

Registration Number: NCT00280150

Locations: 🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States
🇺🇸
Batte Cancer Center at Northeast Medical Center, Concord, North Carolina, United States
🇺🇸
Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States

Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Biological: sargramostim
Biological: therapeutic autologous dendritic cells
Biological: trastuzumab
Drug: vinorelbine ditartrate

First Posted Date: 2005-12-15

Last Posted Date: 2018-09-12

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 17

Registration Number: NCT00266110

Locations: 🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States

Oxaliplatin, Gemcitabine, Erlotinib, and Radiation Therapy in Treating Patients With Unresectable and/or Metastatic Pancreatic Cancer or Biliary Tract Cancer

Phase 1

Completed

Conditions: Extrahepatic Bile Duct Cancer
Gallbladder Cancer
Pancreatic Cancer

Interventions: Drug: gemcitabine hydrochloride
Drug: erlotinib hydrochloride
Drug: Oxaliplatin
Radiation: radiation therapy

First Posted Date: 2005-12-15

Last Posted Date: 2012-03-07

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 23

Registration Number: NCT00266097

Locations: 🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States

Octreotide in Treating Patients With Locally Advanced or Metastatic Liver Cancer

Phase 2

Completed

Conditions: Liver Cancer

First Posted Date: 2005-11-22

Last Posted Date: 2012-02-14

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 31

Registration Number: NCT00257426

Locations: 🇺🇸
The University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy